Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium and orphenadrine citrate, the active ingredient in Neodolpasse, is a nonsteroidal anti‑inflammatory drug and muscle relaxant presented as an intravenous formulation for acute pain and muscle spasm management in adults. It is indicated for post‑operative pain, musculoskeletal pain and muscle spasm relief.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neodolpasse combines an NSAID and a muscle‑relaxant to address pain and spasm in the musculoskeletal system. - Post‑operative pain: provides analgesia and reduces inflammation after surgery. - Musculoskeletal pain: alleviates pain associated with joint, tendon or ligament disorders. - Muscle spasm: relaxes skeletal muscle and diminishes spasm‑related discomfort.

Neodolpasse may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient episodes. - Injection site reactions: erythema, pain or swelling at the infusion site.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis, angioedema. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Renal impairment: acute kidney injury, especially in susceptible patients. - Bleeding disorders: gastrointestinal ulceration or hemorrhage.

Before prescribing Neodolpasse, clinicians should consider several safety aspects. - Renal function: monitor in patients with existing kidney disease. - Cardiovascular risk: use cautiously in patients with heart disease or hypertension. - Gastrointestinal ulcer: avoid in individuals with active ulcer disease. - Drug interactions: review concomitant NSAIDs, anticoagulants or lithium. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Neodolpasse can interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Concurrent NSAIDs: increased risk of gastrointestinal bleeding. - Anticoagulants (warfarin, DOACs): heightened bleeding risk. - Lithium: enhanced lithium toxicity. - Methotrexate: reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: potential electrolyte imbalance. - Corticosteroids: additive ulcer risk.